The optimal use of cyclosporin A in autoimmune diseases.
The optimal use of cyclosporin (CsA) in autoimmune diseases aims at achieving the best risk/benefit ratio and ensuring the absence of potentially irreversible adverse effects, particularly with respect to the kidney [corrected]. The experience gained with CsA therapy in more than 3,000 patients with autoimmune diseases is the basis for the current recommendations: the initial dose should be the lowest effective one and not exceed 5 mg/kg/day in non-life-threatening conditions; treatment should be as brief as possible (2-4 months) in cases of inefficacy; once a satisfactory clinical improvement has been achieved, the treatment should be maintained in the long-term using the lowest individually titrated effective dose; the dose of CsA should be decreased when serum creatinine rises by more than 30% above pre-CsA level. Continuous clinical and biological monitoring (especially of blood pressure and serum creatinine) is mandatory as long as CsA is prescribed. When these conditions are fulfilled, CsA may be an effective and safe therapy for selected autoimmune diseases, even in long-term treatment.
Feutren
G
G
Clinical Research/Immunology, Sandoz Pharma Ltd, Basle, Switzerland.
D001327:Autoimmune Diseases / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008223:Lymphoma / Q000139:chemically induced
D016572:Cyclosporine